Cost-effectiveness of anti-vascular endothelial growth factor and macular laser treatments for people with centre-involving diabetic macular oedema and central retinal thickness of at least 400 micrometres
Given their clinical and cost-effectiveness at confidential prices, NICE recommends offering a licensed cost-effective anti-VEGF as first-line treatment for people with CI-DMO and CRT ≥ 400 µm. The use of bevacizumab for this population is not licensed in the UK and would be considered off-label.
Authors
- Kate Kelley (ORCID: https://orcid.org/0000-0001-9719-1082)
- Philip I. Burgess (ORCID: https://orcid.org/0000-0002-3959-2299)
- Hannah Tebbs
- Syed Mohiuddin (ORCID: https://orcid.org/0000-0003-4585-3392)
- Nichole Taske
- Lindsay Claxton (ORCID: https://orcid.org/0000-0002-1795-7568)
- Christiana Dinah (ORCID: https://orcid.org/0000-0002-0815-4771)
- Noemi Lois (ORCID: https://orcid.org/0000-0003-2666-2937)
- Kirsty Luckham (ORCID: https://orcid.org/0009-0009-2131-6243)
- A.H. Yosef
- Clare Dadswell
Institutions
- Queen's University Belfast (GB)
- University of Liverpool (GB)
- Aintree University Hospitals NHS Foundation Trust (GB)
- London North West Healthcare NHS Trust (GB)
- National Institute for Health and Care Excellence (GB)
- BMT Group (United Kingdom) (GB)
Publication Details
- Journal
- Eye
- Published
- 2025-09-19
- DOI
- https://doi.org/10.1038/s41433-025-04015-6
- Citations
- 2
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.41